Marjanka K Schmidt

List of Publications by Citations

272 papers	16,284 citations	64 h-index	121 g-index
306 ext. papers	19,936 ext. citations	9 avg, IF	5.21 L-index

#	Paper	IF	Citations
272	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, **2013**, 45, 353-61, 361e1-2	36.3	813
271	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
270	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616
269	A common coding variant in CASP8 is associated with breast cancer risk. *Nature Genetics*, **2007**, 39, 352-8	36.3	557
268	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of the National Cancer Institute*, **2011**, 103, 250-63	9.7	513
267	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
266	Rare and low-frequency coding variants alter human adult height. *Nature*, **2017**, 542, 186-190	50.4	412
265	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406
264	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature*, **2014**, 514, 92-97	50.4	401
263	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*, **2009**, 41, 585-90	36.3	393
262	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
261	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2	36.3	327
260	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
259	Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. *British Journal of Cancer*, **2005**, 93, 287-92	8.7	269
258	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nature Genetics*, **2017**, 49, 834-841	36.3	257
257	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nature Genetics*, **2011**, 43, 1210-4	36.3	253
256	Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nature Genetics*, **2012**, 44, 312-8	36.3	237

255	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Human Mutation*, **2012**, 33, 100-3	4.7	230
254	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
253	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. *Breast Cancer Research and Treatment*, **2009**, 116, 295-302	4.4	222
252	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*, **2019**, 21, 1708-1718	8.1	192
251	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
250	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American Journal of Human Genetics*, **2013**, 92, 489-503	11	167
249	Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6340-5	11.5	151
248	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
247	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011** , 20, 3289-303	5.6	140
246	CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 4308-16	2.2	134
245	Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. *Lancet Oncology, The*, **2009**, 10, 1070-6	21.7	133
244	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. *Annals of Oncology*, **2011**, 22, 1561-1570	10.3	131
243	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *British Journal of Cancer*, **2012**, 107, 800-7	8.7	130
242	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
241	The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. *Annals of Oncology*, **2010**, 21, 717-722	10.3	115
240	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genetics*, **2013**, 9, e1003284	6	112
239	Gene-environment interaction and risk of breast cancer. *British Journal of Cancer*, **2016**, 114, 125-33	8.7	108
238	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *Journal of Clinical Oncology*, **2016**, 34, 2750-60	2.2	107

237	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
236	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
235	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, **2017**, 19, 58	8.3	100
234	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. *Cancer Research*, **2011**, 71, 6240-9	10.1	100
233	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
232	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. *Cancer Research*, **2012**, 72, 1795-803	10.1	93
231	Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. *Journal of Clinical Oncology*, **2007**, 25, 64-9	2.2	92
230	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
229	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications*, **2014**, 4, 4999	17.4	87
228	The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. *European Journal of Human Genetics*, **2007**, 15, 110-4	5.3	85
227	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *Journal of Medical Genetics*, **2016**, 53, 298-309	5.8	83
226	Independent prognostic value of screen detection in invasive breast cancer. *Journal of the National Cancer Institute*, **2011**, 103, 585-97	9.7	83
225	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
224	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *American Journal of Human Genetics*, **2013**, 93, 1046-60	11	80
223	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Medicine*, **2016**, 13, e1002105	11.6	80
222	Breast tumors induced by high-dose radiation display similar genetic profiles. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
221	Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
220	Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. *Breast Cancer Research*, **2005**, 7, 1	8.3	78

219	Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. *Current Drug Safety*, **2013**, 8, 333-48	1.4	77
218	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
217	Weekly supplementation with iron and vitamin A during pregnancy increases hemoglobin concentration but decreases serum ferritin concentration in Indonesian pregnant women. *Journal of Nutrition*, **2001**, 131, 85-90	4.1	76
216	Association of ESR1 gene tagging SNPs with breast cancer risk. *Human Molecular Genetics*, **2009**, 18, 1131-9	5.6	75
215	The role of genetic breast cancer susceptibility variants as prognostic factors. *Human Molecular Genetics*, **2012**, 21, 3926-39	5.6	75
214	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	74
213	Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. *Cancer Research*, **2007**, 67, 9584-90	10.1	69
212	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011**, 20, 4693-706	5.6	66
211	Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. *Journal of Clinical Oncology*, **2016**, 34, 409-18	2.2	65
210	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
209	Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. *PLoS ONE*, **2015**, 10, e0120189	3.7	65
208	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nature Reviews Clinical Oncology*, **2020**, 17, 687-705	19.4	64
207	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
206	Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. *Breast Cancer Research*, **2007**, 9, R26	8.3	60
205	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics*, **2015**, 96, 5-20	11	59
204	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
203	CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. *Journal of Medical Genetics*, **2011**, 48, 860-3	5.8	54
202	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. *International Journal of Epidemiology*, **2018**, 47, 526-536	7.8	53

201	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
200	Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1610-6	4	53
199	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2019**, 48, 795-806	7.8	52
198	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genetics in Medicine*, **2017**, 19, 599-603	8.1	51
197	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, -like status, tumor-infiltrating immune cells and survival. *OncoImmunology*, **2018**, 7, e1509820	7.2	51
196	Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. *Cancer Research*, **2017**, 77, 2789-2799	10.1	49
195	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
194	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
193	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
192	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
191	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
190	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. *Breast Cancer Research*, **2019**, 21, 90	8.3	45
189	Long-term impact of the 70-gene signature on breast cancer outcome. *Breast Cancer Research and Treatment*, **2014**, 143, 587-92	4.4	45
188	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. *Breast Cancer Research*, **2016**, 18, 104	8.3	44
187	Mammographic screening detects low-risk tumor biology breast cancers. *Breast Cancer Research and Treatment*, **2014**, 144, 103-11	4.4	44
186	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. *EBioMedicine*, **2015**, 2, 681-9	8.8	44
185	Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 230-4	4	44
184	Nutritional status and linear growth of Indonesian infants in west java are determined more by prenatal environment than by postnatal factors. *Journal of Nutrition*, **2002**, 132, 2202-7	4.1	43

183	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *American Journal of Human Genetics*, **2016**, 99, 903-911	11	43
182	A role for XRCC2 gene polymorphisms in breast cancer risk and survival. *Journal of Medical Genetics*, **2011**, 48, 477-84	5.8	42
181	Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. *Diabetologia*, **2017**, 60, 1691-1703	10.3	41
180	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	40
179	Identification of novel genetic markers of breast cancer survival. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	38
178	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genetics*, **2014**, 10, e1004285	6	38
177	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Medicine*, **2015**, 13, 156	11.4	37
176	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
175	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84	5.6	36
174	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
173	Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. *Breast Cancer Research*, **2015**, 17, 100	8.3	35
172	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *Human Molecular Genetics*, **2014**, 23, 2490-7	5.6	35
171	Weekly vitamin A and iron supplementation during pregnancy increases vitamin A concentration of breast milk but not iron status in Indonesian lactating women. *Journal of Nutrition*, **2001**, 131, 2664-9	4.1	35
170	Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. *Breast Cancer Research and Treatment*, **2016**, 159, 553-63	4.4	34
169	11q13 is a susceptibility locus for hormone receptor positive breast cancer. *Human Mutation*, **2012**, 33, 1123-32	4.7	33
168	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
167	Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. *Annals of Surgery*, **2018**, 267, 952-958	7.8	31
166	Exceptions to the rule of informed consent for research with an intervention. *BMC Medical Ethics*, **2016**, 17, 9	2.9	31

165	Use of metformin and survival of diabetic women with breast cancer. *Current Drug Safety*, **2013**, 8, 357-63	1.4	31
164	Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis. *Breast Cancer Research and Treatment*, **2011**, 130, 561-8	4.4	31
163	Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2143-51	4	31
162	A trial of consent procedures for future research with clinically derived biological samples. *British Journal of Cancer*, **2009**, 101, 1505-12	8.7	31
161	Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. *Breast Cancer Research*, **2009**, 11, R89	8.3	31
160	Mental and psychomotor development in Indonesian infants of mothers supplemented with vitamin A in addition to iron during pregnancy. *British Journal of Nutrition*, **2004**, 91, 279-86	3.6	31
159	Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Research*, **2016**, 18, 22	8.3	31
158	Vitamin A and iron supplementation of Indonesian pregnant women benefits vitamin A status of their infants. *British Journal of Nutrition*, **2001**, 86, 607-15	3.6	30
157	Diabetes and Breast Cancer Subtypes. *PLoS ONE*, **2017**, 12, e0170084	3.7	29
156	Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 934-45	4	29
155	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
154	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46	5.6	28
153	Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*, **2021**, 596, 393-397	50.4	28
152	The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype. *Journal of the National Cancer Institute*, **2019**, 111, 709-718	9.7	27
151	Body mass index and breast cancer survival: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2017**, 46, 1814-1822	7.8	27
150	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2222-31	4	27
149	Obtaining 'fresh' consent for genetic research with biological samples archived 10 years ago. *European Journal of Cancer*, **2009**, 45, 1168-1174	7.5	27
148	The spectrum of ATM missense variants and their contribution to contralateral breast cancer. *Breast Cancer Research and Treatment*, **2008**, 107, 243-8	4.4	27

147	Randomised double-blind trial of the effect of vitamin A supplementation of Indonesian pregnant women on morbidity and growth of their infants during the first year of life. *European Journal of Clinical Nutrition*, **2002**, 56, 338-46	5.2	27
146	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *American Journal of Human Genetics*, **2015**, 97, 22-34	11	26
145	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. *Breast Cancer Research*, **2017**, 19, 119	8.3	26
144	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *International Journal of Cancer*, **2015**, 136, E685-96	7.5	26
143	Opt-out plus, the patients' choice: preferences of cancer patients concerning information and consent regimen for future research with biological samples archived in the context of treatment. *Journal of Clinical Pathology*, **2009**, 62, 275-8	3.9	26
142	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26
141	Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. *Breast Cancer Research*, **2016**, 18, 98	8.3	26
140	The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. *Breast Cancer Research and Treatment*, **2017**, 166, 435-445	4.4	25
139	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
138	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. *Breast*, **2019**, 44, 1-14	3.6	25
137	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Human Molecular Genetics*, **2016**, 25, 3863-3876	5.6	24
136	Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. *Annals of Surgery*, **2019**, 270, 364-372	7.8	24
135	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genetic Epidemiology*, **2014**, 38, 84-93	2.6	24
134	Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Research*, **2015**, 17, 58	8.3	24
133	Genetic variants in TGF1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. *Radiotherapy and Oncology*, **2012**, 102, 115-21	5.3	24
132	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma -A Nested Case-Control Study. *Clinical Cancer Research*, **2018**, 24, 3593-3601	12.9	23
131	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. *European Journal of Cancer*, **2017**, 78, 37-44	7.5	22
130	Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. *Breast Cancer Research and Treatment*, **2013**, 139, 811-9	4.4	21

129	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
128	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
127	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nature Communications*, **2020**, 11, 312	17.4	20
126	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *British Journal of Cancer*, **2014**, 110, 1088-100	8.7	20
125	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. *Scientific Reports*, **2018**, 8, 6574	4.9	19
124	Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. *Breast Cancer Research and Treatment*, **2014**, 145, 697-705	4.4	19
123	SNP-SNP interaction analysis of NF-B signaling pathway on breast cancer survival. *Oncotarget*, **2015**, 6, 37979-94	3.3	19
122	Determinants of weight and length of Indonesian neonates. *European Journal of Clinical Nutrition*, **2002**, 56, 947-51	5.2	19
121	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. *Journal of Pathology: Clinical Research*, **2015**, 1, 18-32	5.3	18
120	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
119	The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. *International Journal of Cancer*, **2020**, 146, 2296-2304	7.5	18
118	Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 835-845	4	17
117	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. *Breast Cancer Research*, **2015**, 17, 18	8.3	17
116	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1680-91	4	17
115	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. *Genetics in Medicine*, **2020**, 22, 1803-1811	8.1	17
114	Excess breast cancer risk in first degree relatives of CHEK2*1100delC positive familial breast cancer cases. *European Journal of Cancer*, **2013**, 49, 1993-9	7.5	17
113	9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1783-91	4	17
112	ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. *BMC Cancer*, **2008**, 8, 105	4.8	17

111	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. *International Journal of Epidemiology*, **2020**, 49, 1117-1131	7.8	17
110	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. *Blood*, **2019**, 133, 1130-1139	2.2	17
109	The BRCA2 c.68-7T□□A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Human Mutation*, **2018**, 39, 729-741	4.7	16
108	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). *Scientific Reports*, **2016**, 6, 32512	4.9	16
107	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. *Journal of Pathology: Clinical Research*, **2016**, 2, 138-53	5.3	16
106	An information-theoretic analysis of genetics, gender and age in cancer patients. *PLoS ONE*, **2008**, 3, e1951	3.7	16
105	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
104	Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review. *Pharmacoepidemiology and Drug Safety*, **2015**, 24, 897-905	2.6	15
103	Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. *Annals of Oncology*, **2013**, 24, 2036-42	10.3	15
102	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes and Control*, **2016**, 27, 679-93	2.8	15
101	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. *Journal of Medical Genetics*, **2020**, 57, 509-518	5.8	14
100	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. *Oncotarget*, **2015**, 6, 7390-407	3.3	14
99	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *Journal of the National Cancer Institute*, **2021**, 113, 329-337	9.7	14
98	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. *International Journal of Cancer*, **2017**, 141, 1830-1840	7.5	13
97	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. *Nature Communications*, **2014**, 5, 4051	17.4	13
96	A response to "Personalised medicine and population health: breast and ovarian cancer". *Human Genetics*, **2019**, 138, 287-289	6.3	13
95	Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. *American Journal of Surgical Pathology*, **2019**, 43, 1574-1582	6.7	13
94	Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. *International Journal of Epidemiology*, **2020**, 49, 216-232	7.8	13

93	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis*, **2015**, 36, 256-71	4.6	12
92	Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. *European Journal of Human Genetics*, **2015**, 23, 588-95	5.3	12
91	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
90	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Research*, **2014**, 16, R51	8.3	12
89	The role of Indonesian patients' health behaviors in delaying the diagnosis of nasopharyngeal carcinoma. *BMC Public Health*, **2017**, 17, 510	4.1	12
88	Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. *European Journal of Cancer*, **2014**, 50, 1045-54	7.5	12
87	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
86	Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study. *Familial Cancer*, **2015**, 14, 355-63	3	11
85	Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012. *European Journal of Cancer* , **2018**, 101, 134-142	7.5	11
84	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46	5.6	11
83	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS ONE*, **2016**, 11, e0160316	3.7	11
82	Prediction and clinical utility of a contralateral breast cancer risk model. *Breast Cancer Research*, **2019**, 21, 144	8.3	11
81	An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint). *European Journal of Cancer*, **2017**, 75, 5-13	7.5	10
80	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
79	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. *EBioMedicine*, **2019**, 48, 203-211	8.8	9
78	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
77	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. *International Journal of Cancer*, **2018**, 143, 746-757	7.5	9
76	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. *International Journal of Cancer*, **2013**, 132, 2044-55	7.5	9

75	The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. *Breast Cancer Research*, **2017**, 19, 26	8.3	9
74	Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. *Breast Cancer Research and Treatment*, **2011**, 130, 599-608	4.4	9
73	Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding. *European Journal of Cancer*, **2009**, 45, 2376-82	7.5	9
72	The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study. *PLoS ONE*, **2016**, 11, e0151899	3.7	9
71	Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries. *Diabetes Care*, **2019**, 42, 434-442	14.6	8
70	Connective tissue: Cancer patients attitudes towards medical research using excised (tumour) tissue. *BioSocieties*, **2011**, 6, 466-486	1.5	8
69	Trends in breast cancer incidence among women with type-2 diabetes in British general practice. *Primary Care Diabetes*, **2017**, 11, 373-382	2.4	7
68	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. *Breast Cancer Research and Treatment*, **2020**, 181, 423-434	4.4	7
67	Long-term prognosis of young breast cancer patients (40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. *BMJ Open*, **2017**, 7, e017842	3	7
66	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. *Oncotarget*, **2017**, 8, 18381-18398	3.3	7
65	Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. *BMC Medicine*, **2020**, 18, 327	11.4	7
64	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. *International Journal of Cancer*, **2021**, 148, 2289-2303	7.5	7
63	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. *Drug and Alcohol Dependence*, **2018**, 188, 94-101	4.9	7
62	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
61	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. *BMC Cancer*, **2018**, 18, 224	4.8	6
60	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. *BMC Cancer*, **2015**, 15, 978	4.8	6
59	Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. **2009**,		6
58	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. *Oncotarget*, **2017**, 8, 113531-113542	3.3	6

57	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *International Journal of Epidemiology*, **2021**,	7.8	6
56	Patients' Attitudes Towards the Return of Incidental Findings After Research with Residual Tissue: A Mixed Methods Study. *Genetic Testing and Molecular Biomarkers*, **2018**, 22, 178-186	1.6	5
55	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. *British Journal of Cancer*, **2016**, 114, 298-304	8.7	5
54	Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. *Cancer Biology and Therapy*, **2014**, 15, 371-9	4.6	5
53	Tumour tissue: who is in control?. *Lancet Oncology, The*, **2010**, 11, 9-11	21.7	5
52	Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. *Journal of Community Genetics*, **2019**, 10, 61-71	2.5	5
51	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. *British Journal of Cancer*, **2011**, 105, 1934-9	8.7	4
50	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102019	2.2	4
49	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. *JAMA Oncology*, **2022**,	13.4	4
48	A Randomised Controlled Trial of Consent Procedures for the Use of Residual Tissues for Medical Research: Preferences of and Implications for Patients, Research and Clinical Practice. *PLoS ONE*, **2016**, 11, e0152509	3.7	4
47	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2021**, 113, 893-899	9.7	4
46	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
45	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 623-642	4	4
44	Breast Cancer Susceptibility□owards Individualised Risk Prediction. *Current Genetic Medicine Reports*, **2019**, 7, 124-135	2.2	3
43	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3
42	Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients. *PLoS ONE*, **2017**, 12, e0189750	3.7	3
41	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
40	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3

39	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
38	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2
37	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. *Scientific Reports*, **2016**, 6, 36874	4.9	2
36	Effectiveness of a multicentre nasopharyngeal carcinoma awareness programme in Indonesia. *BMJ Open*, **2016**, 6, e008571	3	2
35	Abstract 2030: The role of genetic variation in calcium-activated potassium channels in breast cancer patients treated with tamoxifen **2016**,		2
34	Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries		2
33	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2
32	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. *Npj Breast Cancer*, **2021**, 7, 52	7.8	2
31	Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 399-410	4.4	2
30	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
29	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *British Journal of Cancer*, **2021**, 124, 842-854	8.7	2
28	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. *Journal of Clinical Oncology*, **2022**, JCO2101536	2.2	2
27	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. *Breast*, **2020**, 50, 95-103	3.6	1
26	The BIO-PIN paradigm: 'access to' or 'return of' results?. *Nature Reviews Cancer*, **2011**, 11, 895; author reply 895	31.3	1
25	Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences		1
24	Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. *Annals of Oncology*, **2021**,	10.3	1
23	Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?. *Advances in Breast Cancer Research*, **2015**, 04, 87-99	0.1	1
22	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1

21	Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers		1
20	Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility		1
19	Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ		1
18	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
17	Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk. *Scientific Reports*, **2016**, 6, 30026	4.9	1
16	Recall and Retention of Consent Procedure Contents and Decisions: Results of a Randomized Controlled Trial. *Public Health Genomics*, **2018**, 21, 27-36	1.9	1
15	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86	8.3	1
14	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. *British Journal of Cancer*, **2021**, 125, 1443-1449	8.7	1
13	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3 polymorphisms and gene co-expression. *Npj Breast Cancer*, **2021**, 7, 118	7.8	1
12	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium **2014**, n/a-n/a		1
11	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
10	Germline breast cancer susceptibility genes, tumor characteristics, and survival. *Genome Medicine*, **2021**, 13, 185	14.4	0
9	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.. *Breast*, **2021**, 61, 98-107	3.6	0
8	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Scientific Reports*, **2021**, 11, 19787	4.9	0
7	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. *Npj Breast Cancer*, **2020**, 6, 60	7.8	0
6	Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'. *Breast Cancer Research and Treatment*, **2021**, 188, 821-823	4.4	0
5	Browser-based Data Annotation, Active Learning, and Real-Time Distribution of Artificial Intelligence Models: From Tumor Tissue Microarrays to COVID-19 Radiology. *Journal of Pathology Informatics*, **2021**, 12, 38	4.4	0
4	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0

3	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention.. *Preventive Medicine*, **2022**, 107075	4.3	0
2	Breast cancer risks associated with missense variants in breast cancer susceptibility genes.. *Genome Medicine*, **2022**, 14, 51	14.4	0
1	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. *Obstetrical and Gynecological Survey*, **2015**, 70, 758-762	2.4	